Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.
Stocks · News reference
Filed: 2026-09-01 AccNo: 0000049071-26-000052 Size: 150 KB Item 7.01: Regulation FD Disclosure
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.
The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000049071/000004907126000052/hum-20260901.htm